Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.48 |
| ▸ | PARP11 | Q9NR21 | 4/20 | 0.48 |
| ▸ | PARP1 | P09874 | 4/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463796 | 1.00 | FABP6 (0.60) | FABP6PARP10PARP11PARP1PDPK1 | |
| Hydrochloric Acid SCHEMBL29731561 | 0.98 | FABP6 (0.58) | FABP6PARP10PARP11PARP1PDPK1 | |
| SCHEMBL23196172 | 0.89 | FABP6 (0.49) | FABP6PARP10PARP11PARP1PDPK1 | |
| SCHEMBL331587 | 0.80 | PKM (0.50) | FABP6PARP10PARP11PARP1PDPK1 | |
| SCHEMBL2171078 | 0.80 | PKM (0.50) | FABP6PARP10PARP11PARP1PDPK1 | |
| SCHEMBL22743863 | 0.79 | FABP6 (0.58) | FABP6PARP10PARP11PARP1PDPK1 | |
| SCHEMBL21780364 | 0.79 | FABP6 (0.61) | FABP6PARP10PARP11GSK3BKDM4E | |
| SCHEMBL25796465 | 0.79 | PARP10 (0.57) | FABP6PARP10PARP11GSK3BKDM4E | |
| SCHEMBL12849451 | 0.78 | FABP6 (0.42) | FABP6PKMTSHRJAK2NTRK1 | |
| SCHEMBL15814048 | 0.77 | FABP6 (0.51) | FABP6PARP10PARP11JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| WO-2024101965-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | 에스케이바이오팜 주식회사 | 2024-05-16 | — | — | WO | claimed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | claimed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | claimed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | claimed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-02-28 | — | — | US | claimed |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2022-12-22 | — | — | US | claimed |
| CN-114929691-A | Bicyclic compounds and uses thereof | 爱思开生物制药株式会社 | 2022-08-19 | — | — | CN | claimed |
| EP-4039686-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2022-08-10 | — | — | EP | claimed |
| CN-112079826-B | Steroid synthetase inhibitor and treatment application thereof | 广州中医药大学(广州中医药研究院) | 2022-07-29 | — | — | CN | claimed |
| WO-2022057142-A1 | STEROID SYNTHETASE INHIBITORS AND THERAPEUTIC USE THEREOF | 广州中医药大学(广州中医药研究院) | 2022-03-24 | — | — | WO | claimed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | claimed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | claimed |
| EP-2726466-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| WO-2013006485-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | claimed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | disclosed |
| US-12577227-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-12577227-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250197390-A1 | FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-4495119-A1 | FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-01-22 | — | — | EP | disclosed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118496156-A | Compounds with STING inhibition activity, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024163956-A2 | SIGMA RECEPTOR LIGAND COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024101965-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | 에스케이바이오팜 주식회사 | 2024-05-16 | — | — | WO | disclosed |
| EP-4341262-A1 | AXL INHIBITOR COMPOUNDS | Arcus Biosciences, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| CN-117337288-A | AXL inhibitor compounds | 艾库斯生物科学有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117242073-A | PRMT5 inhibitors and uses thereof | 海思科医药集团股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4276095-A2 | PROCESSES FOR PREPARING ASK1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| WO-2023138317-A1 | COMPOUND HAVING RIPK1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023138433-A2 | AMIDE COMPOUND HAVING RIPK1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-07-27 | — | — | WO | disclosed |
| CN-116478135-A | Amide compound having RIPK1 inhibitory activity, process for producing the same and use thereof | 中国科学院上海药物研究所 | 2023-07-25 | — | — | CN | disclosed |
| EP-3693366-B1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023109918-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-06-22 | — | — | WO | disclosed |
| CN-116265452-A | Nitrogen-containing heterocyclic compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-20 | — | — | CN | disclosed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2022-12-22 | — | — | US | disclosed |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2022-12-22 | — | — | US | disclosed |
| WO-2022246179-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2022206964-A1 | PRMT5 INHIBITOR AND USE THEREOF | 海思科医药集团股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| CN-114929691-A | Bicyclic compounds and uses thereof | 爱思开生物制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| EP-4039686-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2022-08-10 | — | — | EP | disclosed |
| US-20220242849-A1 | WDR5 INHIBITORS AND MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-04 | — | — | US | disclosed |
| US-20220242849-A1 | WDR5 INHIBITORS AND MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-04 | — | — | US | disclosed |
| WO-2022057142-A1 | STEROID SYNTHETASE INHIBITORS AND THERAPEUTIC USE THEREOF | 广州中医药大学(广州中医药研究院) | 2022-03-24 | — | — | WO | disclosed |
| US-11111237-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-09-07 | — | — | US | disclosed |
| US-11111237-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-09-07 | — | — | US | disclosed |
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210101892-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2021-04-08 | — | — | US | disclosed |
| US-20210101892-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2021-04-08 | — | — | US | disclosed |
| WO-2021066578-A1 | BICYCLIC COMPOUND AND USE THEREOF | 에스케이바이오팜 주식회사 | 2021-04-08 | — | — | WO | disclosed |
| WO-2020247679-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020228436-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2020-11-19 | — | — | WO | disclosed |
| EP-3237404-B1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3101013-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200283393-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3666772-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
| EP-3088395-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3098218-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3085694-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3085696-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2018-06-28 | — | — | US | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9890134-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20180022708-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-01-25 | — | — | US | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| WO-2017188287-A1 | SUBSTITUTED PURINE DERIVATIVE | 大日本住友製薬株式会社 | 2017-11-02 | — | — | WO | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9771328-B2 | Processes for preparing ASK1 inhibitors | GILEAD SCIENCES, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771328-B2 | Processes for preparing ASK1 inhibitors | GILEAD SCIENCES, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9745339-B2 | Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20170233350-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233350-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233368-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-9676760-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676760-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9670187-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670187-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9598435-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598435-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9586933-B2 | Processes for preparing ASK1 inhibitors | GILEAD SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586933-B2 | Processes for preparing ASK1 inhibitors | GILEAD SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-3101013-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160347744-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160347744-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| EP-3098218-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160332977-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160332977-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160332976-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160332976-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| EP-3088395-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-3085694-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3085696-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| CN-106029654-A | Preparation of 3, 4-dihydro-1, 4-benzoxazepin-5 (2H) -one derivatives by cyclization of 2- (aminoethoxy) benzoic acid derivatives | 吉利德科学公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-3070081-A1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | Gilead Sciences, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160244430-A1 | Processes for preparing ASK1 inhibitors | GILEAD SCIENCES, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244430-A1 | Processes for preparing ASK1 inhibitors | GILEAD SCIENCES, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| WO-2016106384-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-2726466-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20160096846-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096846-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-04-07 | — | — | US | disclosed |
| EP-2788336-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193694-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193694-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2935238-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2015123519-A2 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225384-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225384-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-9040515-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2838898-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2015-02-25 | — | — | EP | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| EP-2812346-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | Graffinity Pharmaceuticals GmbH (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-2788336-A1 | BENZOTHIAZOL- 6 -YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | Gilead Sciences, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2421854-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014097041-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140135317-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135317-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2726466-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8697863-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| WO-2014020152-A1 | LIGANDS FOR APHERESIS AND IMMUNOABSORPTION | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-8586732-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586732-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013157022-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013159064-A1 | BENZOTHIAZOL- 6 -YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| WO-2013117707-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-08-15 | — | — | WO | disclosed |
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| WO-2013006485-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2489657-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| EP-2489657-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| US-8222245-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (S1P) | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2421854-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| US-7947833-B2 | methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010122038-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273771-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100173890-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100174065-A1 | COMPOUNDS | GLAXO GROUP LIMITED (US) | 2010-07-08 | — | — | US | disclosed |
| US-7749996-B2 | Heterotricyclic metalloprotease inhibitors | Alantos Pharmaceutical Holdings, Inc. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-7691851-B2 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2139887-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | Alantos Pharmaceuticals Holding, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2134693-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| EP-2125816-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2102211-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2099803-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-2099792-A1 | HETEROTRICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-2094707-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-2094671-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-2038283-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1989198-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF CANCER, INFECTIONS, INFLAMMATORY AND AUTOIMMUNE DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| EP-1981855-A2 | SUBSTITUTED BIS-AMIDE METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008109177-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109181-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109179-A1 | METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109178-A1 | METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109180-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221094-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080221091-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008063669-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063670-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063668-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063667-A1 | HETEROTRICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1910367-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910321-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | ALLISON BRETT D | 2008-03-27 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7288651-B2 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| WO-2007096351-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF CANCER, INFECTIONS, INFLAMMATORY AND AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007079199-A2 | SUBSTITUTED BIS-AMIDE METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, HOLDING, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1651622-B1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2007004959-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | WO | disclosed |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1651621-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651622-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| US-7008938-B2 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | NOKIA CORPORATION (FI) | 2006-03-07 | — | — | US | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005016897-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016896-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-6809092-B2 | 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | disclosed |
| US-6489322-B1 | BENZOXAZEPINES AS SELECTIVE INHIBITORS OF THE NEURONAL ISOFORM OF NITRIC OXIDE SYNTHASE FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ASTRAZENECA AB (SE) | 2002-12-03 | — | — | US | disclosed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0755930-B1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LTD (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-0983268-B1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| EP-0757986-B1 | Arylpiperidine and arylpiperazine derivatives and drugs containing the same | SUNTORY LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-6319916-B1 | CHOLINESTERASE INHIBITOR FOR SENILE DEMENTIA AND ALZHEIMER'S TREATMENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-0567090-B1 | Benzoxazepine derivatives as cholinesterase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0983268-A1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | Astra Aktiebolag (SE) | 2000-03-08 | — | — | EP | disclosed |
| EP-0925288-A1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999003847-A1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998050382-A1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRA AKTIEBOLAG (SE) | 1998-11-12 | — | — | WO | disclosed |
| US-5723475-A | Arylpiperidine and arylpiperazine derivatives and medicament containing the same | SUNTORY LIMITED (JP) | 1998-03-03 | — | — | US | disclosed |
| EP-0757986-A1 | ARYLPIPERIDINE AND ARYLPIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0755930-A1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
| EP-0463810-B1 | Heterocyclic compound and psychopharmaceutical composition containing same | SUNTORY LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5475021-A | Administering N-substituted succinimides | VANDERBILT UNIVERSITY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995015163-A1 | NOVEL COMPOUNDS FOR INHIBITION OF CYCLOOXYGENASE ACTIVITY | VANDERBILT UNIVERSITY (US) | 1995-06-08 | — | — | WO | disclosed |
| EP-0376633-B1 | Benzoxazepine derivatives | SUNTORY LTD (JP) | 1994-10-12 | — | — | EP | disclosed |
| EP-0567090-A2 | Benzoxazepine derivatives as cholinesterase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-5158947-A | CONDENSED HETEROCYCLIC COMPOUNDS AND PSYCHOPHARMACEUTICAL COMPOSITION CONTAINING SAME | SUNTORY LIMITED (JP) | 1992-10-27 | — | — | US | disclosed |
| EP-0463810-A1 | Heterocyclic compound and psychopharmaceutical composition containing same | SUNTORY LIMITED (JP) | 1992-01-02 | — | — | EP | disclosed |
| US-5071845-A | Psychotropic or anxyiolytic agent | SUNTORY LIMITED (JP) | 1991-12-10 | — | — | US | disclosed |
| EP-0376633-A2 | Benzoxazepine derivatives | SUNTORY LIMITED (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0376633-A2 | Benzoxazepine derivatives | SUNTORY LIMITED (JP) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | FABP6 3978/4885PARP10 1998/4885PARP11 1918/4885 |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | FABP6 2812/4885PARP10 780/4885PARP11 647/4885 |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | FABP6 3743/4885PARP10 58/4885PARP11 78/4885 |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | FABP6 2174/4885PARP10 635/4885PARP11 362/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | FABP6 3064/4885PARP10 1785/4885PARP11 668/4885 |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DGAT1, DGAT2, CPT1A | FABP6 477/4885PARP10 2234/4885PARP11 1186/4885 |
| US-20170233350-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | MAP3K1, MAP3K6, MAP3K7 | FABP6 3771/4885PARP10 1650/4885PARP11 612/4885 |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | FABP6 2308/4885PARP10 628/4885PARP11 233/4885 |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | FABP6 4771/4885PARP10 1865/4885PARP11 956/4885 |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | FABP6 2688/4885PARP10 2161/4885PARP11 1984/4885 |
| US-20160332976-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | KCNN2, KCNJ2, KCNN1 | FABP6 4332/4885PARP10 3571/4885PARP11 3953/4885 |
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | FABP6 22/4885PARP10 3716/4885PARP11 3744/4885 |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, MMP10 | FABP6 2647/4885PARP10 361/4885PARP11 270/4885 |
| US-20170233368-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | FABP6 4771/4885PARP10 1865/4885PARP11 956/4885 |
| US-20200283393-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | MAP3K1, MAP3K6, MAP3K7 | FABP6 3771/4885PARP10 1650/4885PARP11 612/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | FABP6 2911/4885PARP10 380/4885PARP11 300/4885 |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | FABP6 4771/4885PARP10 1865/4885PARP11 956/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | FABP6 2763/4885PARP10 380/4885PARP11 288/4885 |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | PRMT5, PRMT1, PRMT6 | FABP6 4062/4885PARP10 29/4885PARP11 18/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | FABP6 2911/4885PARP10 380/4885PARP11 300/4885 |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | FABP6 2688/4885PARP10 2161/4885PARP11 1984/4885 |
| US-20250197390-A1 | FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, MLKL | FABP6 3372/4885PARP10 601/4885PARP11 386/4885 |
| US-20160332977-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | KCNN2, KCNJ2, KCNN1 | FABP6 4332/4885PARP10 3571/4885PARP11 3953/4885 |
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | FABP6 2183/4885PARP10 1336/4885PARP11 714/4885 |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | FABP6 2688/4885PARP10 2161/4885PARP11 1984/4885 |
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | FABP6 22/4885PARP10 3716/4885PARP11 3744/4885 |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | FABP6 2251/4885PARP10 1433/4885PARP11 771/4885 |
| US-11111237-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | FABP6 3743/4885PARP10 58/4885PARP11 78/4885 |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | FABP6 3069/4885PARP10 358/4885PARP11 224/4885 |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | FABP6 3840/4885PARP10 304/4885PARP11 302/4885 |
| US-20100174065-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | FABP6 263/4885PARP10 1961/4885PARP11 2130/4885 |
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | FABP6 4824/4885PARP10 638/4885PARP11 641/4885 |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | FABP6 2911/4885PARP10 380/4885PARP11 300/4885 |
| US-20220242849-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | FABP6 1622/4885PARP10 1088/4885PARP11 939/4885 |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | SALL4, NR4A2, NES | FABP6 3364/4885PARP10 491/4885PARP11 1354/4885 |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | FABP6 3743/4885PARP10 58/4885PARP11 78/4885 |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | FABP6 3520/4885PARP10 1582/4885PARP11 1543/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | FABP6 2960/4885PARP10 351/4885PARP11 266/4885 |
| US-20210101892-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | FABP6 3743/4885PARP10 58/4885PARP11 78/4885 |
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | HTR6, HTR3B, HTR5A | FABP6 31/4885PARP10 2448/4885PARP11 3077/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | FABP6 2308/4885PARP10 628/4885PARP11 233/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | FABP6 3520/4885PARP10 1582/4885PARP11 1543/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | FABP6 2308/4885PARP10 628/4885PARP11 233/4885 |
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | MMP11, MMP13, MMP14 | FABP6 3014/4885PARP10 704/4885PARP11 1000/4885 |
| US-20080221094-A1 | Metalloprotease inhibitors containing a squaramide moiety | MMP13, MMP14, MMP11 | FABP6 3390/4885PARP10 660/4885PARP11 663/4885 |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PRMT5, PRMT1, PRMT3 | FABP6 4477/4885PARP10 120/4885PARP11 119/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | FABP6 3511/4885PARP10 1866/4885PARP11 1751/4885 |
| US-20180022708-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | MAP3K1, MAP3K6, MAP3K7 | FABP6 3771/4885PARP10 1650/4885PARP11 612/4885 |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT8 | FABP6 3808/4885PARP10 78/4885PARP11 99/4885 |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | BACH1, BACE1, CMA1 | FABP6 2973/4885PARP10 3652/4885PARP11 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.